Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

RHEI Pharmaceuticals starts final trial of Tibozole in China

RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China.

8 Dec 2008

Smart materials to revolutionise surgical implants

A brand new process that could revolutionise the reliability and durability of surgical implants, such as hip and knee replacements, has today, 2 December 08, received recognition for its medical and commercial potential by achieving one of the world's most sought after accolades.

2 Dec 2008

Nanoparticle reports on drug delivery to breast tumors, predicts response to therapy

One of the hallmarks of many nanoparticle-based anticancer therapeutics and imaging agents is that they accumulate in tumors thanks to the fact that they are small enough to escape from the bloodstream through the leaky blood vessels that surround tumors.

20 Nov 2008

Nontoxic nanoparticle delivers and tracks drugs

A nontoxic nanoparticle developed by Penn State researchers is proving to be an all-around effective delivery system for both therapeutic drugs and the fluorescent dyes that can track their delivery.

18 Nov 2008

Innocoll receives fast track designation for Gentamicin surgical implant

Innocoll, Inc., a privately-held biopharmaceutical company, announced that the FDA has designated Gentamicin surgical implant as a Fast Track development program.

17 Nov 2008

TheraQuest's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA

TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.

13 Nov 2008

Phosphagenics' diclofenac enters trial phase in humans

Phosphagenics Limited ("Phosphagenics") announced today that it has initiated a phase 1 human clinical trial using its patented drug delivery system, TPM, for the targeted delivery of a leading non steroidal anti-inflammatory drug (NSAID), diclofenac.

12 Nov 2008

Further evidence that angiogenesis drugs can be much more effective when combined with chemotherapy

Scientists have thought that one way to foil a tumor from generating blood vessels to feed its growth - a process called angiogenesis - was by creating drugs aimed at stopping a key vessel growth-promoting protein.

10 Nov 2008

SurModics acquires drug delivery assets of PR Pharmaceuticals

SurModics, Inc. announced today that it has acquired a portfolio of intellectual property and collaborative drug delivery projects from PR Pharmaceuticals, Inc., a drug delivery company specializing in injectable, biodegradable sustained release formulations.

4 Nov 2008

Titan Pharmaceuticals updates on Probuphine patent application

Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company's method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain.

31 Oct 2008

Starpharma's VivaGelR patent approved in Japan

Starpharma Holdings Limited today announced that one of its key patents relating to the use of dendrimers to protect against sexually transmitted infections has been approved in Japan.

29 Oct 2008

Nanodiamond drug device could transform cancer treatment

A team of investigators at Northwestern University has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.

27 Oct 2008

Near-infrared nanoparticles shine a bright light on cancer

A new nanoparticle-enabled imaging method for breast cancer has been developed by a team of scientists from Penn State. Their research, utilizing encapsulated fluorescent molecules in calcium phosphate nanoparticles and nontoxic near infrared (NIR) imaging, appears in the journal ACS Nano.

27 Oct 2008

Teva granted FDA approval for Fentanyl transdermal system

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil's chronic pain treatment Duragesic. Shipment of this product has commenced.

20 Oct 2008

neuMirRx issued U.S. patent for "methods for enhancing solubility of compounds

neuMirRx Corp today welcomed the issuance of U.S. patent 7,345,093, entitled "Methods for Enhancing Solubility of Compounds" which covers novel formulation methods to enhance the solubility of hydrophobic compounds.

15 Oct 2008

Nanoparticles, so small, seep right through the skin

Scientists are warning that tiny particles - nanoparticles - are so small that they can be absorbed through the skin.

1 Oct 2008

When particles are so small that they seep right through skin

Scientists are finding that particles that are barely there - tiny objects known as nanoparticles that have found a home in electronics, food containers, sunscreens, and a variety of applications - can breech our most personal protective barrier: The skin.

30 Sep 2008

Hybrid nanoparticles image and treat tumors

By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.

28 Sep 2008

Nanotubes detect tumors and deliver high-potency punch

Researchers at the Center for Cancer Nanotechnology Excellence Focused on Therapy Response (CCNE-TR), based at Stanford University, have found a new way to target cancer cells while leaving healthy cells untouched.

28 Sep 2008

Review of drug delivery market

Combating losses due to patent expiries has become a high priority for pharmaceutical companies. Investing in new drug delivery technologies is becoming a critical strategy for them to maintain a strong presence in this cut-throat market as they offer the potential to enhance the life cycle of established drugs.

18 Sep 2008